Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

RED-C 3131 Study

Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C)

liver illustration
AGE: 18 – 85 years old
TYPE: Interventional Drug Study
CONDITION: Liver disease, Hepatic encephalopathy, Cirrhosis
LOCATION: UH Cleveland Medical Center

Learn More

For more information, please contact the study coordinator, Antonio Levert at 216-286-7069 or complete the online form below.

Study Purpose

The purpose of this research study is to see if an investigational drug, Rifaximin SSD-40IR, given twice daily, will help delay the first episode of overt hepatic encephalopathy requiring hospitalization in patients with liver cirrhosis and how safe it is to use in people.

Who Can Participate

Participants between 18 to 85 years of age with a diagnosis of liver disease at risk for hepatic encephalopathy may be eligible for this study.

Request More Information

To learn more about this study, please fill out the form below to request more information.

I'm not a robot

  • STUDY20220521